The Motley Fool

Don’t waste the stock market crash! FTSE 100 shares I’d buy for the next 10 years

This month’s stock market crash has been a wild ride. The FTSE 100 has lost around 20% of its value in less than 30 days. The big cap index is now back at the same level it was 10 years ago.

This may seem like a poor advert for stock market investing. But I’d argue that it’s more likely to be a significant buying opportunity. The crash has dragged most companies down, without looking too closely at individual businesses.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

However, when the market recovers, I expect stronger companies to regain their historical lead. Today I’m going to look at three FTSE 100 shares I’d buy for the next 10 years.

A defensive growth industry

I already own some shares in FTSE 100 pharmaceutical group GlaxoSmithKline (LSE: GSK). But I’m hoping to buy more while the share price is down. I’m pretty sure that demand for the group’s medicines – which include cancer treatments and vaccines – should continue to grow over the next decade.

Despite this, the GSK share price has fallen by about 15% so far this year. I’m pretty sure that’s a decent buying opportunity. Despite attracting investor criticism at times, Glaxo has actually outperformed the FTSE 100 by around 20% over the last 10 years. It’s also paid generous dividends.

The group has not yet issued a trading update relating to Covid-19, which suggests to me that its performance this year should not be severely affected by the pandemic.

The sell-off has pushed Glaxo’s dividend yield up to about 5.3% and left the stock trading on 12 times forecast earnings. I rate the shares as a buy at this level.

This FTSE 100 firm is up 130% in 10 years

Drinks giant Diageo (LSE: DGE) is another defensive business that’s hammered the FTSE 100 over the last decade. The Diageo share price has risen by 133% since March 2010, compared to a gain of just 3% for the FTSE 100.

Diageo’s products are even more profitable than those sold by GlaxoSmithKline. This is thanks to the reliable appeal of brands such as Gordon’s, Johnnie Walker and Guinness.

Of course, it’s not all plain sailing. Diageo expects to sales to fall by up to £325m this year as a result of the coronavirus pandemic. Operating profit is expected to fall by between £140m and £200m, depending on the timing of any recovery.

These numbers could get worse, in my view. But it’s worth remembering that the group’s operating profit last year was nearly £4.2bn. This business can take the hit without too many problems, thanks to high profit margins and a solid balance sheet.

Diageo isn’t the cheapest stock out there. Even after recent falls, the shares trade on nearly 20 times forecast earnings and yield just 2.9%.

However, this FTSE 100 stalwart has a fantastic track record of sustained growth. I suspect this will continue. I see this as a low-risk buy for a long-term portfolio.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Diageo. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.